NKTRNEKTAR THERAPEUTICSvs its industry peers
A metric-by-metric comparison of NEKTAR THERAPEUTICS against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NKTREsta | $2.4B#4 | — | 2.6x#2 | 42.6x#3 | -43.9%#4 | -37.8%#4 | -253.7%#2 | -18.2%#3 | -14.0%#2 | — | 34.7%#2 | — |
| IRON | $2.7B#1 | — | 4.1x#4 | — | — | -94.0%#5 | — | -32.9%#4 | -39.0%#3 | — | 13.9%#3 | — |
| VRDN | $2.5B#2 | — | 3.8x#3 | 35.2x#2 | 23359.9%#1 | -26.9%#3 | -512.9%#3 | -51.7%#5 | -54.5%#4 | — | — | — |
| HRMY | $2.5B#3 | 13.7x#1 | 2.5x#1 | 2.8x#1 | 21.5%#3 | 9.1%#2 | 24.0%#1 | 15.9%#1 | 25.5%#1 | 4#1 | — | — |
| TRVI | $2.2B#5 | — | 6.7x#5 | — | — | 10.7%#1 | — | -13.3%#2 | — | — | 90.1%#1 | — |
| ZBIO | $2.1B#6 | — | 8.7x#6 | 214.0x#4 | 100.0%#2 | -140.6%#6 | -3830.6%#4 | -152.9%#6 | -296.6%#5 | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice